Dr. Jamal G. Misleh, MD

Dr. Misleh practices at Pathology Hematology Hgcc - HOPD in Newark, Delaware.

Dr. Misleh's NPI, 1174665822, was assigned on February 12, 2007. Dr. Misleh graduated from University of Miami, Lm Miller School of Medicine in 2003. Dr. Misleh holds Delaware license C1-0008987.

Dr. Misleh's primary practice is Pathology Hematology Hgcc - HOPD, at 4701 Ogletown Stanton Rd, Newark, DE 19713.

Dr. Misleh's primary practice is Pathology Hematology Hgcc - HOPD in Newark, Delaware. Dr. Misleh is also affiliated with Christiana Hospital. The medical group on file is Medical Oncology Hematology Consultants, PA. Dmand AI also links Dr. Misleh to 4 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account. Dr. Misleh's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Misleh practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Misleh's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Misleh is board certified in hematology by the American Board of Internal Medicine. Dr. Misleh is licensed in Delaware.

CMS data shows 269,889 Medicare services from Dr. Misleh across 60 procedure codes in 2024, for 822 Medicare patients. Medicare paid $7,405,895 for them.

CMS counts 822 Medicare patients who saw Dr. Misleh in 2024. The largest group is 65 to 74, with 332 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.37, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Misleh's median patient age at 71, with 52% women.

In 2024, Dr. Misleh wrote 2,585 Medicare Part D claims for 362 patients. 76% of them were for generic drugs. CMS names the drug for 2,178 of them, across 49 drugs with 11 or more claims each, at $7,742,779 in total drug cost. In 2023, CMS named 2,385 claims across 48 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Misleh for performance year 2024, reported individually. Dr. Misleh accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Misleh as offering telehealth.

Dmand AI links 14 papers to Dr. Misleh, published from 2011 to 2025. 2023 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, Cognition and Leukemia, Lymphocytic, Chronic, B-Cell. Dr. Misleh's most frequent co-authors are Gregory A. Masters, MD, John McEvoy Burke, MD and Aileen Cleary Cohen, MD.

Dmand AI links Dr. Misleh to 10 clinical trials, 3 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Glioblastoma. Loxo Oncology, Inc. sponsors the most, 2. Open Payments lists research payments to Dr. Misleh that name 1 trial.

CMS Open Payments shows 73 general payments to Dr. Misleh from 30 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 98% of the total. Bristol-Myers Squibb Company paid the most, $436. It also lists 3 research payments totaling $2,752 from 2021 to 2025, naming 1 clinical trial.

Dr. Misleh graduated from University of Miami, Lm Miller School of Medicine in 2003.